Is survival enough for myelodysplastic syndromes?
Santini
Valeria
V
D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005260:Female; D005858:Germany; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000401:mortality* / Q000628:therapy*; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D033581:Stem Cell Transplantation; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage; D014184:Transplantation, Homologous; D014635:Valproic Acid / Q000008:administration & dosage
D000961:Antilymphocyte Serum; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D003561:Cytarabine; D013792:Thalidomide; D014635:Valproic Acid